Search results for "chronic liver disease"

showing 10 items of 165 documents

Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP.

2012

Chronic liver disease promotes hepatocellular injury involving apoptosis and triggers compensatory regeneration that leads to the activation of quiescent stellate cells in the liver. The deposition of extracellular matrix from activated myofibroblasts promotes hepatic fibrosis and the progression to cirrhosis with deleterious effects on liver physiology. The role of apoptosis signaling pathways in the development of fibrosis remains undefined. The aim of the current study was to determine the involvement of the caspase-8 homologue cellular FLICE-inhibitory protein (cFLIP) during the initiation and progression of fibrosis. Liver injury and fibrosis from carbon tetrachloride (CCl4) and thioa…

Liver CirrhosisMalePathologymedicine.medical_specialtyTime FactorsGenotypePhysiologyCASP8 and FADD-Like Apoptosis Regulating ProteinApoptosisBiologyThioacetamideChronic liver diseaseMicePhysiology (medical)medicineAnimalsMitogen-Activated Protein Kinase 9PhosphorylationExtracellular Signal-Regulated MAP KinasesCarbon TetrachlorideCompensatory regenerationLiver injuryMice KnockoutHepatologyCaspase 3Gastroenterologymedicine.diseaseCaspase 9Enzyme ActivationDisease Models Animalmedicine.anatomical_structurePhenotypeLiverApoptosisHepatocyteHepatic stellate cellCancer researchDisease ProgressionHepatocytesHepatocellular injuryChemical and Drug Induced Liver InjuryHepatic fibrosisSignal TransductionAmerican journal of physiology. Gastrointestinal and liver physiology
researchProduct

Performance of morphologic criteria for the diagnosis of cirrhosis in patients with non-alcoholic steatohepatitis compared to other etiologies of chr…

2020

Purpose To compare the diagnostic performance of morphologic criteria for detection of cirrhosis in patients with alcoholic liver disease (ALD), hepatitis C (HCV), and non-alcoholic steatohepatitis (NASH). Methods One hundred patients (53 male) with different etiologies of chronic liver disease (NASH,n = 41; HCV,n = 39; and ALD,n = 20) and with different degrees of fibrosis on histopathologic examination (74 with cirrhosis) were retrospectively evaluated. Four readers (R1: fellowship-trained abdominal radiologist, R2: community attending radiologist, R3: senior radiology resident/research fellow, R4: junior radiology resident) analyzed the contrast-enhanced CTs for presence of commonly acce…

Liver CirrhosisMalemedicine.medical_specialtyAlcoholic liver diseaseCirrhosisUrologyChronic liver diseaseGastroenterology030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineNon-alcoholic fatty liver diseases (NAFLD)Non-alcoholic Fatty Liver DiseaseInternal medicineAscitesmedicineHumansRadiology Nuclear Medicine and imagingLiver Diseases AlcoholicComputed tomographyRetrospective StudiesRadiological and Ultrasound Technologybusiness.industryGastroenterologyHepatitis CHepatologymedicine.diseaseCirrhosis030220 oncology & carcinogenesisPortal hypertensionSteatohepatitismedicine.symptombusinessNon-alcoholic steatohepatiti
researchProduct

Should cirrhosis change our attitude towards treating non-hepatic cancer?

2011

Cirrhosis is a major cause of morbidity and mortality and is the end stage of any chronic liver disease. Cancer, a leading cause of death worldwide, is a growing global health issue. There are limited data in the literature on the incidence, prevalence and management of non-hepatic cancers (NHC) in cirrhotic patients. The aim of this brief review was to underline the main concerns, pitfalls and warnings regarding practice for these patients. Survival of patients with compensated cirrhosis is significantly longer than that of decompensated cirrhosis and patients with NHC and in Child-Pugh class C should not be candidates for cytotoxic chemotherapy. It is important before starting cytotoxic c…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisAntineoplastic AgentsComorbidityChronic liver diseaseGastroenterologyLiver diseaseInternal medicineCause of DeathNeoplasmsmedicineHumansIntensive care medicineSurvival rateCause of deathHepatologybusiness.industryPatient SelectionCancerProfessional Practicemedicine.diseasechemotherapy – cirrhosis – hepatotoxicity – non-hepatic cancerClinical trialSurvival RateClinical Trials Phase III as TopicPortal hypertensionFemaleChemical and Drug Induced Liver InjurybusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Health-related quality of life in patients with compensated and decompensated liver cirrhosis.

2019

Compensated (Child-Pugh [CP] A) and decompensated (CP B/C) liver cirrhosis significantly differs in terms of impairment of health-related quality of life (HRQoL). However, sufficient data on potentially treatable factors associated with HRQoL in both stages of the disease are still lacking. Consequently, aims of this study were to determine differences in HRQoL between patients with compensated and decompensated liver cirrhosis and to identify potentially treatable factors associated with HRQoL.218 patients with liver cirrhosis were enrolled into this study. Chronic Liver Disease Questionnaire (CLDQ) was used to assess HRQoL. Covert hepatic encephalopathy (CHE) was diagnosed according to a …

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisPsychometricsDisease030204 cardiovascular system & hematologyChronic liver diseaseGastroenterologySeverity of Illness Index03 medical and health sciences0302 clinical medicineQuality of lifeRisk FactorsInternal medicineGermanySurveys and QuestionnairesInternal MedicinemedicineHumansRoutine clinical practiceIn patient030212 general & internal medicineProspective StudiesHepatic encephalopathyAgedHealth related quality of lifebusiness.industryMiddle Agedmedicine.diseasehumanitiesHepatic EncephalopathyMultivariate AnalysisLinear ModelsQuality of LifeFemalebusinessEuropean journal of internal medicine
researchProduct

Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases.

2006

In 2001, 6,999 anti-HCV positive subjects referred to 79 Italian hospital in a 6 months enrollment period were evaluated. Of them, 5,632 (80.5%) tested anti-HCV positive alone, 1,163 (16.6%) reported also an excessive alcohol intake, and 204 (2.9%) were also HBsAg positive. Normal biochemistry was observed in 7.8% of cases, chronic hepatitis in 67.9% of cases, liver cirrhosis in 18.9% of cases, and hepatocellular carcinoma in 3.6% cases. HCV positive subjects with excessive alcohol intake were statistically significantly younger, of male sex, and having more severe liver disease than those without excessive alcohol intake. Adjusting for the confounding effect of age and sex by multiple logi…

Liver CirrhosisMalemedicine.medical_specialtyHBsAgCirrhosisCarcinoma HepatocellularAlcohol DrinkingHepacivirusHepacivirusChronic liver diseaseHCV PositiveLiver diseaseVirologyInternal medicinePrevalenceMedicineHumansHepatologybiologybusiness.industryIncidence (epidemiology)Incidencechronic liver diseaseHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseSurgeryHCV infectionInfectious DiseasesItalyHepatocellular carcinomaRegression AnalysisFemalebusinessJournal of viral hepatitis
researchProduct

Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats

2020

BACKGROUND AND AIMS Portal hypertension is the main consequence of cirrhosis, responsible for the complications defining clinical decompensation. The only cure for decompensated cirrhosis is liver transplantation, but it is a limited resource and opens the possibility of regenerative therapy. We investigated the potential of primary human amniotic membrane-derived mesenchymal stromal (hAMSCs) and epithelial (hAECs) stem cells for the treatment of portal hypertension and decompensated cirrhosis. METHODS In vitro: Primary liver sinusoidal endothelial cells (LSECs) and hepatic stellate cells (HSCs) from cirrhotic rats (chronic CCl4 inhalation) were co-cultured with hAMSCs, hAECs or vehicle for…

Liver CirrhosisPathologymedicine.medical_specialtyhAECCirrhosisplacentaPortal venous pressure03 medical and health sciences0302 clinical medicineHypertension PortalSettore BIO/13 - BIOLOGIA APPLICATAAnimalsHumansMedicineAmnion610 Medicine & healthHepatologymedicine.diagnostic_testbusiness.industryMicrocirculationStem Cellschronic liver diseaseportal hypertensionEndothelial CellsAmniotic stem cellsmedicine.diseaseRatsLiver030220 oncology & carcinogenesisHepatic stellate cellPortal hypertensionVascular Resistance030211 gastroenterology & hepatologyStem cellbusinessHepatic fibrosisLiver function testshAMSCLiver International
researchProduct

SARS-CoV-2 infection in patients with a normal or abnormal liver.

2020

Abstract Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), a novel coronavirus causing coronavirus disease 19 (COVID‐19), with an estimated 22 million people infected worldwide so far although involving primarily the respiratory tract, has a remarkable tropism for the liver and the biliary tract. Patients with SARS‐CoV‐2 infection and no antecedent liver disease may display evidence of cytolytic liver damage, proportional to the severity of COVID‐19 but rarely of clinical significance. The mechanism of hepatocellular injury is unclear and possibly multifactorial. The clinical impact of SARS‐CoV‐2 infection in patients with underlying chronic liver disease, a cohort whose global …

Liver CirrhosisRiskmedicine.medical_specialtyCirrhosisCOVID-19 VaccinesCOVID-19 VaccineLiver CirrhosiPopulationDiseaseChronic liver diseasemedicine.disease_causeSARS‐CoV‐2Liver diseaseCOVID‐19VirologyInternal medicinevaccinemedicineHumansClinical significanceeducationCoronaviruseducation.field_of_studySettore MED/12 - GastroenterologiaHepatologybusiness.industryTransmission (medicine)SARS-CoV-2Liver DiseasescirrhosisCOVID-19chronic liver diseaseprioritizationmedicine.diseaseInfectious DiseasesLiverNon‐commissioned ReviewChronic DiseasebusinesscirrhosiHumanJournal of viral hepatitis
researchProduct

Color Doppler Ultrasound in Portal Hypertension

2020

Portal hypertension is one of the most important causes of morbidity and mortality in cirrhotic patients. A color Doppler evaluation of the left gastric vein (LGV) has proven utility in the prediction of esophageal varices and variceal bleeding in patients with portal hypertension. The purpose of this review is to discuss the ultrasound evaluation, imaging findings, and clinical application of Doppler ultrasound in the assessment of the LGV. Knowledge of the color Doppler technique and imaging findings of the LGV may help clinicians improve the monitoring of portal hypertension and predict patients with a high risk of esophageal varices.

Liver Cirrhosisesophageal varicemedicine.medical_specialtyleft gastric veinLeft gastric veinHemodynamicsEsophageal and Gastric Varicesurologic and male genital diseasesChronic liver disease030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineEsophageal varicesHypertension PortalHumansMedicineRadiology Nuclear Medicine and imagingUltrasonography Doppler Color030219 obstetrics & reproductive medicineRadiological and Ultrasound TechnologyPortal Veinultrasoundbusiness.industryUltrasoundHemodynamicschronic liver diseaseportal hypertensionColor doppler ultrasoundColor dopplermedicine.diseasefemale genital diseases and pregnancy complicationsPortal hypertensionRadiologycolor DopplerGastrointestinal HemorrhagebusinessJournal of Ultrasound in Medicine
researchProduct

Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma

2012

Interleukin-6 (IL-6) is a pleiotropic cytokine which is expressed in many inflammatory cells in response to different types of stimuli, regulating a number of biological processes. The IL-6 gene is polymorphic in both the 5’ and 3’ flanking regions and more than 150 single nucleotide polymorphisms have been identified so far. Genetic polymorphisms of IL-6 may affect the outcomes of several diseases, where the presence of high levels of circulating IL-6 have been correlated to the stage and/or the progression of the disease itself. The -174 G/C polymorphism is a frequent polymorphism, that is located in the upstream regulatory region of the IL-6 gene and affects IL-6 production. However, the…

Liver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusSingle-nucleotide polymorphismBiologyChronic liver diseasemedicine.disease_causePolymorphism Single NucleotideGastroenterologyHepatitis B ChronicNon-alcoholic Fatty Liver DiseaseRisk FactorsChronic hepatitis Hepatocellular carcinoma Interleukin-6 Liver cirrhosis Single nucleotide polymorphismsInternal medicineGenotypemedicineHumansGenetic Predisposition to DiseaseTopic HighlightLiver Diseases AlcoholicInterleukin-6Liver NeoplasmsFatty liverGastroenterologyGeneral MedicineHepatitis C ChronicHepatitis Bmedicine.diseaseFatty LiverHepatitis AutoimmunePhenotypeHepatocellular carcinomaImmunologySteatohepatitisWorld Journal of Gastroenterology
researchProduct

Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensate…

2021

[Background & Aims] Patients with advanced fibrosis related to nonalcoholic fatty liver disease (NAFLD) are at risk of developing hepatic and extrahepatic complications. We investigated whether, in a large cohort of patients with NAFLD and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) and their changes can be used to identify patients at risk for liver-related and extrahepatic events.

Liver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularSettore MED/09 - Medicina InternaNASH; cACLD; prognostic factor; steatohepatitis[SDV]Life Sciences [q-bio]cACLD; NASH; Prognostic Factor; Steatohepatitis; Gastrointestinal Hemorrhage; Humans; Liver; Liver Cirrhosis; Retrospective Studies; Carcinoma Hepatocellular; Elasticity Imaging Techniques; Esophageal and Gastric Varices; Liver Neoplasms; Non-alcoholic Fatty Liver Disease610 Medicine & healthEsophageal and Gastric VaricesChronic liver diseaseGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInterquartile rangeInternal medicineAscitesNonalcoholic fatty liver diseasemedicineHumansComputingMilieux_MISCELLANEOUSRetrospective StudiesSteatohepatitisHepatologybusiness.industryPrognostic FactorsteatohepatitiCarcinomaLiver NeoplasmsHazard ratioGastroenterologyNASHHepatocellularcACLDmedicine.disease3. Good healthLiver030220 oncology & carcinogenesisHepatocellular carcinomaElasticity Imaging Techniques030211 gastroenterology & hepatologySteatohepatitismedicine.symptomGastrointestinal HemorrhageTransient elastographybusiness
researchProduct